- Cetrorelix acetate
-
-
2026-09-11
- CAS:130143-01-0
- Min. Order: 1g
- Purity: 98%min
- Supply Ability: 1000g
- Cetrorelix diacetate
-
- $50.00
-
2026-08-25
- CAS:130143-01-0
- Min. Order: 10kg
- Purity: 0.99
- Supply Ability: 20tons
- Cetrorelix acetate
-
- $1.00
-
2026-01-14
- CAS:130143-01-0
- Min. Order: 10g
- Purity: 99
- Supply Ability: 999
|
| | Cetrorelix acetate Basic information |
| Product Name: | Cetrorelix acetate | | Synonyms: | N-Acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-L-tyrosyl-N5-(aminocarbonyl)-D-ornithyl-L-leucyl-L-arginyl-L-prolyl-D-alaninamide diacetate;Cetrorenlin Acetate;Cetrelix Acetate;Cetrorelix Diacetate;Cetrorelix AcetateQ: What is
Cetrorelix Acetate Q: What is the CAS Number of
Cetrorelix Acetate;NS-75A diacetate;SB-075 diacetate;(S)-N-((R)-1-Amino-1-oxopropan-2-yl)-1-((2S,5S,8R,11S,14S,17R,20R,23R)-20-(4-chlorobenzyl)-2-(3-guanidinopropyl)-11-(4-hydroxybenzyl)-14-(hydroxymethyl)-5-isobutyl-23-(naphthalen-2-ylmethyl)-4,7,10,13,16,19,22,25-octaoxo-17-(pyridin-3-ylmethyl)-8-(3-ureidopropyl)-3,6,9,12,15,18,21,24-octaazahexacosan-1-oyl)pyrrolidine-2-carboxamide diacetate | | CAS: | 130143-01-0 | | MF: | C70H92N17O14 | | MW: | 1551.16 | | EINECS: | | | Product Categories: | 130143-01-0 | | Mol File: | 130143-01-0.mol |  |
| | Cetrorelix acetate Chemical Properties |
| storage temp. | under inert gas (nitrogen or Argon) at 2-8°C | | solubility | DMSO:50.0(Max Conc. mg/mL);33.53(Max Conc. mM)
Water:2.0(Max Conc. mg/mL);1.34(Max Conc. mM) | | Sequence | Ac-3-(2-naphthyl)-D-Ala-4-Chloro-D-Phe-3(3-pyridyl)-D-Ala-Ser-Tyr-D-Cit-Leu- | | InChIKey | JUIDLEJONVXAMD-SFKTYWRYNA-N | | CAS DataBase Reference | 130143-01-0(CAS DataBase Reference) |
| | Cetrorelix acetate Usage And Synthesis |
| Uses | Cetrorelix diacetate (SB-075 diacetate) is a potent gonadotropin-releasing hormone (GnRH) receptor antagonist with an IC50 of 1.21 nM[1]. | | Clinical Use | Cetrorelix acetate is an analogue of GnRH with amino acid substitutions at residues 1, 2, 3, 6,
and 10 and differing from ganirelix at amino acids 1, 6, and 8. Each of these
substitutions are synthetic, non-DNA-directed amino acids and, like ganirelix acetate, impart
GnRH antagonist activity to cetrorelix acetate. This drug also is marketed for use in women
undergoing assisted reproductive therapy (ART) procedures, in which it is necessary to control
their LH surge. This allows the follicles to develop to a size, as determined by ultrasound, that
increases the success of timed insemination and oocyte retrieval for IVF. Like ganirelix acetate,
cetrorelix acetate has an advantage over GnRH agonists, such as leuprolide acetate, because it
reduces the fertility therapy cycle to days rather than weeks. | | References | [1] Beckers T et al. Characterization of gonadotropin-releasing hormone analogs based on a sensitive cellular luciferase reporter gene assay. Anal Biochem. 1997 Aug 15;251(1):17-23. DOI:10.1006/abio.1997.2208
[2] Gründker C et al. Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer. Reprod Biol Endocrinol. 2003 Oct 7;1:65. DOI:10.1186/1477-7827-1-65 |
| | Cetrorelix acetate Preparation Products And Raw materials |
|